BR112017008660A2 - stable protein solution formulation containing high concentration of an anti-vegf antibody - Google Patents

stable protein solution formulation containing high concentration of an anti-vegf antibody

Info

Publication number
BR112017008660A2
BR112017008660A2 BR112017008660A BR112017008660A BR112017008660A2 BR 112017008660 A2 BR112017008660 A2 BR 112017008660A2 BR 112017008660 A BR112017008660 A BR 112017008660A BR 112017008660 A BR112017008660 A BR 112017008660A BR 112017008660 A2 BR112017008660 A2 BR 112017008660A2
Authority
BR
Brazil
Prior art keywords
high concentration
protein solution
formulation containing
containing high
vegf antibody
Prior art date
Application number
BR112017008660A
Other languages
Portuguese (pt)
Inventor
Kulshreshtha Alok
Boring Charles
Zhang Huixiang
Alani Laman
Wan Li
Zeng Yuhong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017008660(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017008660A2 publication Critical patent/BR112017008660A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção proporciona anticorpos anti-vegf formulados como composições farmacêuticas aquosas, de alta concentração, adequados para uma injeção, preferivelmente uma injeção intravítrea. as composições farmacêuticas aquosas são úteis para a liberação de uma alta concentração do ingrediente ativo de anticorpo para um paciente, sem altos níveis de agregação do anticorpo e sem um alto nível de matéria particulada subvisível. uma composição aquosa da invenção compreende um anticorpo tendo uma concentração de pelo menos 50 mg/ml. uma composição farmacêutica aquosa da invenção inclui um açúcar, um agente de tamponamento, e um tensoativo.The present invention provides anti-vegf antibodies formulated as high concentration aqueous pharmaceutical compositions suitable for an injection, preferably an intravitreal injection. Aqueous pharmaceutical compositions are useful for releasing a high concentration of antibody active ingredient to a patient, without high levels of antibody aggregation and without a high level of subvisible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg / ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.

BR112017008660A 2014-11-07 2015-11-06 stable protein solution formulation containing high concentration of an anti-vegf antibody BR112017008660A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (1)

Publication Number Publication Date
BR112017008660A2 true BR112017008660A2 (en) 2017-12-26

Family

ID=54697654

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112017008660A BR112017008660A2 (en) 2014-11-07 2015-11-06 stable protein solution formulation containing high concentration of an anti-vegf antibody
BR112017008093-1A BR112017008093A2 (en) 2014-11-07 2015-11-06 processes for treating eye diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017008093-1A BR112017008093A2 (en) 2014-11-07 2015-11-06 processes for treating eye diseases

Country Status (24)

Country Link
US (5) US10689438B2 (en)
EP (2) EP3215122A1 (en)
JP (5) JP6753848B2 (en)
KR (3) KR20170082526A (en)
CN (3) CN107635580A (en)
AU (6) AU2015342815B2 (en)
BR (2) BR112017008660A2 (en)
CA (2) CA2966758A1 (en)
CL (2) CL2017001117A1 (en)
CO (1) CO2017004596A2 (en)
EA (1) EA201790989A1 (en)
EC (1) ECSP17034829A (en)
GT (1) GT201700096A (en)
IL (5) IL251642B (en)
MX (3) MX2017005874A (en)
MY (2) MY193913A (en)
NZ (1) NZ730821A (en)
PE (1) PE20170780A1 (en)
PH (2) PH12017500843A1 (en)
RU (1) RU2722643C2 (en)
SG (3) SG10201913565RA (en)
TN (1) TN2017000128A1 (en)
TW (4) TWI806150B (en)
WO (2) WO2016073918A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (en) 2006-04-07 2012-03-20 The Procter & Gamble Company ANTIBODIES BINDING TO HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES OF THE SAME
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN102076716A (en) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Stable and soluble antibodies inhibiting tnfa
JP5856480B2 (en) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー Humanization of rabbit antibodies using a versatile antibody framework
RU2519123C2 (en) 2009-07-06 2014-06-10 Аэрпио Терапьютикс Инк. Compounds, compositions and methods for prevention of metastatic cancer cells
SG10201509193UA (en) 2011-01-13 2015-12-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
EP2766043A4 (en) 2011-10-13 2015-06-10 Aerpio Therapeutics Inc Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
MX2017009759A (en) 2015-01-28 2017-10-27 Pfizer Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation.
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
MX2018003542A (en) 2015-09-23 2018-11-09 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2.
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CA3077518C (en) * 2016-09-07 2021-10-19 Frederic Fellouse Synthetic antibodies against vegf and their uses
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
JOP20190103B1 (en) 2016-11-18 2023-09-17 Astellas Pharma Inc Novel anti-human muc1 antibody fab fragment
KR20190130608A (en) 2017-03-22 2019-11-22 노파르티스 아게 Compositions and Methods for Immune Oncology
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
WO2018195912A1 (en) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 Ophthalmic pharmaceutical composition and use thereof
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
BR112020006434A2 (en) 2017-10-06 2020-11-03 Prothena Biosciences Limited anti-transthyretin antibodies
BR112020010483A2 (en) * 2017-11-29 2020-10-20 Prothena Biosciences Limited lyophilized formulation of a monoclonal antibody against transthyretin
IL276383B2 (en) * 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmologic diseases
MX2020009140A (en) * 2018-03-16 2020-09-28 Novartis Ag Methods for treating ocular diseases.
WO2019180261A1 (en) * 2018-03-23 2019-09-26 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
WO2019200006A2 (en) * 2018-04-10 2019-10-17 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
MA52570A (en) 2018-05-10 2021-03-17 Regeneron Pharma FORMULATIONS CONTAINING HIGH CONCENTRATION VEGF RECEPTOR FUSION PROTEINS
EP3856245A4 (en) * 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
CA3115747A1 (en) * 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MA54052A (en) * 2018-10-29 2022-02-09 Hoffmann La Roche ANTIBODY FORMULATION
CA3119179A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
JP7089121B2 (en) * 2018-12-18 2022-06-21 ノバルティス アーゲー Protein solution preparation containing high concentration of anti-VEGF antibody
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202106699A (en) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 Variant aav capsids for intravitreal delivery
CN114269341A (en) 2019-04-29 2022-04-01 视点制药公司 Tie-2 activator targeting Schlemm's canal
CN114599665A (en) 2019-08-16 2022-06-07 应用分子转运公司 Compositions, formulations and interleukin production and purification
CN114786731A (en) 2019-10-10 2022-07-22 科达制药股份有限公司 Methods of treating ocular disorders
CN111217834B (en) 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Nitroxide derivatives of ROCK kinase inhibitors
CN113698478A (en) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 Anti-alpha-hemolysin antibody and stable formulation thereof
KR20220001106A (en) * 2020-06-29 2022-01-05 (주)메디톡스 High concentration anti-VEGF antibody formulation and anti-VEGF antibody for use in the same
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022245739A1 (en) * 2021-05-17 2022-11-24 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN113940997B (en) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 Stable preparation of bispecific antibody
WO2024056058A1 (en) * 2022-09-16 2024-03-21 齐鲁制药有限公司 Stable high-concentration self-buffering pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (en) * 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
EP3753548A1 (en) * 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
KR102095257B1 (en) * 2008-06-25 2020-04-01 노바르티스 아게 Stable and soluble antibodies inhibiting vegf
RU2582244C2 (en) 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Functionalised polypeptides
SG10201509193UA (en) * 2011-01-13 2015-12-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014004521A (en) * 2011-10-20 2014-05-28 Esbatech A Novartis Co Llc Stable multiple antigen-binding antibody.
UA117466C2 (en) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
TWI806150B (en) 2014-11-07 2023-06-21 瑞士商諾華公司 Stable protein solution formulation containing high concentration of an anti-vegf antibody
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
JP2022141923A (en) 2022-09-29
RU2722643C2 (en) 2020-06-02
AU2018274882B2 (en) 2020-07-09
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
RU2020114917A (en) 2020-05-22
TWI705827B (en) 2020-10-01
AU2015342818B2 (en) 2019-01-03
CA2966646A1 (en) 2016-05-12
IL280087B (en) 2022-02-01
AU2020220210A1 (en) 2020-10-01
TN2017000128A1 (en) 2018-10-19
US20160130337A1 (en) 2016-05-12
US10035850B2 (en) 2018-07-31
TW201625221A (en) 2016-07-16
IL251696A0 (en) 2017-06-29
IL280087A (en) 2021-03-01
KR20230066649A (en) 2023-05-16
NZ730821A (en) 2019-11-29
CN114081951A (en) 2022-02-25
TWI806150B (en) 2023-06-21
TWI738632B (en) 2021-09-11
TW202146049A (en) 2021-12-16
SG11201702909QA (en) 2017-05-30
US10689438B2 (en) 2020-06-23
AU2018274882A1 (en) 2018-12-20
CN107635580A (en) 2018-01-26
CL2017001117A1 (en) 2018-01-26
JP2017534638A (en) 2017-11-24
ECSP17034829A (en) 2019-02-28
RU2017119647A (en) 2018-12-07
JP6667519B2 (en) 2020-03-18
CO2017004596A2 (en) 2017-08-31
CA2966758A1 (en) 2016-05-12
JP6753848B2 (en) 2020-09-09
MX2017005875A (en) 2017-06-26
PH12017500843A1 (en) 2017-10-30
IL283561A (en) 2021-07-29
EP3215123A1 (en) 2017-09-13
KR20170082526A (en) 2017-07-14
RU2020114917A3 (en) 2022-01-17
EP3215122A1 (en) 2017-09-13
GT201700096A (en) 2019-10-10
MY183807A (en) 2021-03-16
KR102588846B1 (en) 2023-10-16
IL251642B (en) 2021-02-28
CL2017001115A1 (en) 2018-01-26
US20210340242A1 (en) 2021-11-04
PH12017500844B1 (en) 2017-10-30
MX2021006768A (en) 2021-07-15
SG11201702954XA (en) 2017-05-30
US11098110B2 (en) 2021-08-24
AU2018278870B2 (en) 2020-05-28
TWI761959B (en) 2022-04-21
PE20170780A1 (en) 2017-07-04
IL251642A0 (en) 2017-06-29
US20200270336A1 (en) 2020-08-27
SG10201913565RA (en) 2020-02-27
JP2020079242A (en) 2020-05-28
EA201790989A1 (en) 2017-09-29
TW202103735A (en) 2021-02-01
AU2020244614A1 (en) 2020-11-05
BR112017008093A2 (en) 2018-03-13
KR20170076781A (en) 2017-07-04
JP2020193212A (en) 2020-12-03
US20180298092A1 (en) 2018-10-18
US20160340420A1 (en) 2016-11-24
MX2017005874A (en) 2017-06-26
AU2015342815A1 (en) 2017-05-11
IL265497A (en) 2019-05-30
JP2017538674A (en) 2017-12-28
WO2016073918A1 (en) 2016-05-12
IL283561B (en) 2022-01-01
RU2017119647A3 (en) 2019-05-29
CN106999581A (en) 2017-08-01
JP7080263B2 (en) 2022-06-03
TW201625306A (en) 2016-07-16
AU2020220210B2 (en) 2022-01-20
AU2018278870A1 (en) 2019-01-03
IL265497B (en) 2021-06-30
PH12017500844A1 (en) 2017-10-30
AU2020244614B2 (en) 2023-06-01
WO2016073915A1 (en) 2016-05-12
MY193913A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112017008660A2 (en) stable protein solution formulation containing high concentration of an anti-vegf antibody
CY1122181T1 (en) PHARMACEUTICAL FORM OF ANTIBODY
BR112014027116A2 (en) antibody formulation
BR112018005349A2 (en) An anti-PD-1 antibody preparation and its application in medicine
BR112018008805A2 (en) dual-function proteins and pharmaceutical composition comprising the same
EP4233892A3 (en) Stable anti-ifnar1 formulation
BR112017016636A2 (en) stable liquid formulation for monoclonal antibodies
WO2012076670A3 (en) Antibody formulation
HRP20120903T1 (en) High concentration antibody-containing liquid formulation
BR112016026811A2 (en) antibody formulation
CL2018003178A1 (en) Pharmaceutical composition
NZ702342A (en) Pharmaceutical formulation
CL2021001587A1 (en) Protein solution formulation containing a high concentration of an anti-vegf antibody
MX2019014666A (en) Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof.
AR102572A1 (en) FORMULATION OF STABLE PROTEIN SOLUTION CONTAINING HIGH CONCENTRATION OF AN ANTI-VEGF ANTIBODY

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]